On a normal day (without Trump's tariff saga) the Outcome of Annual Report in US market should have pushed the SP several folds, however the SP is still in decline and we need to understand that we're in ASX not in NASDAQ and , Mr Market is always correct.
The NEU key strengths:
- Most efficient (possibly in ASX) management,
- Record revenue from DAYBUE, Strong cash position,
- Management commitment to share Buy Back Plan,
- Potential FDA update on NNZ -2591 by early April
all above endorses NEU is significantly undervalued
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.88 |
Change
-0.080(0.62%) |
Mkt cap ! $1.602B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.02 | $12.70 | $861.3K | 67.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17 | $12.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.90 | 125 | 1 |
View Market Depth
| Last trade - 10.45am 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |